Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization

被引：100

作者：

Pasi, KJ

Collins, PW

Keeling, DM

Brown, SA

Cumming, AM

Dolan, GC

Hay, CRM

Hill, FGH

Laffan, M

Peake, IR

机构：

[1] Barts & London, Queen Marys Sch Med Dent, Dept Haematol, UKHCDO von Willebrand Dis Working Party, London E1 2AD, England

[2] Univ Wales Hosp, Arthur Bloom Haemophilia Ctr, Cardiff CF4 4XW, S Glam, Wales

[3] Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England

[4] Royal Free Hosp, Dept Haematol, London NW3 2QG, England

[5] Manchester Royal Infirm, Univ Dept Haematol, Manchester M13 9WL, Lancs, England

[6] Queens Med Ctr, Dept Haematol, Nottingham NG7 2UH, England

[7] Childrens Hosp, Dept Haematol, Birmingham B16 8ET, W Midlands, England

[8] Hammersmith Hosp, Imperial Coll, Dept Haematol, London, England

[9] Univ Sheffield, Div Genom Med, Sheffield, S Yorkshire, England

来源：

HAEMOPHILIA | 2004年 / 10卷 / 03期

关键词：

blood products; 1-deamino-8-D-arginine vasopressin; guideline; inherited bleeding disorder; treatment; von Willebrand disease;

D O I：

10.1111/j.1365-2516.2004.00886.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994.

引用

页码：218 / 231

页数：14

共 76 条

[1]

[Anonymous], AC PAIN MAN OP MED P

[2] USE OF A HIGH-PURITY FACTOR-VIII CONCENTRATE (HEMATE-P) IN VONWILLEBRANDS DISEASE [J].

BERNTORP, E ;

NILSSON, IM .

VOX SANGUINIS, 1989, 56 (04) :212-217

[3]

BOND L, 1988, NEW ENGL J MED, V318, P121

[4]

Bonnar J, 1996, BRIT MED J, V313, P579

[5] REEVALUATION OF THE THERAPEUTIC EFFICACY OF DDAVP IN TYPE IIB VON WILLEBRANDS DISEASE [J].

CASONATO, A ;

PONTARA, E ;

DANNHAEUSER, D ;

BERTOMORO, A ;

SARTORI, MT ;

ZERBINATI, P ;

GIROLAMI, A .

BLOOD COAGULATION & FIBRINOLYSIS, 1994, 5 (06) :959-964

[6]

CASONATO A, 1990, EUR J HAEMATOL, V45, P36

[7]

CASONATO A, 1990, THROMB HAEMOSTASIS, V64, P117

[8]

Casonato A, 1999, THROMB HAEMOSTASIS, V81, P224

[9] Desmopressin and type II B von Willebrand disease [J].

Castaman, G ;

Rodeghiero, F .

HAEMOPHILIA, 1996, 2 (02) :73-77

[10]

CASTILLO R, 1991, BLOOD, V77, P1901

← 1 2 3 4 5 6 7 8 →